COMMUNIQUÉS West-GlobeNewswire

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01/02/2024
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients [...]
NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer
01/02/2024
DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the [...]
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Soleno Therapeutics to Present at Upcoming February Investor Conferences
01/02/2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Ibogaine By David Dardashti Shares Insight On New Study By Stanford University
01/02/2024
MIAMI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- According to researchers at Stanford University, ibogaine may have the potential to restore brain function in individuals who have suffered traumatic brain injuries and witnessed [...]
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
01/02/2024
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST — MELVILLE, N.Y., [...]
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
01/02/2024
- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S. Food and Drug [...]
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
01/02/2024
Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
01/02/2024
TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Quipt Home Medical Corp. to Announce Fiscal First Quarter 2024 Financial Results on February 14, 2024
01/02/2024
CINCINNATI, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce [...]
Dyne Therapeutics to Present at February Investor Conferences
01/02/2024
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
01/02/2024
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy metabolism by inhibiting [...]
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
01/02/2024
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process [...]
ITM Obtains Manufacturing License in the U.S.
01/02/2024
License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S. Garching / Munich and Princeton, NJ, February 1, 2024 – ITM [...]
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
01/02/2024
PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim 6 th [...]
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/2024
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and [...]
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
01/02/2024
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta [...]
Applied UV, Inc. to Develop Smart Building Technologies for Larimar City, a New Luxury Development With Six Hotels and 20,000 High-end Residences - Potential Revenues Could Total $250 Million to $300 Million
01/02/2024
Max Munn, CEO of AUVI, states: “We estimate that potential revenues from this project could total $250 Million to $300 Million over the next 3 to 6 years.” AUVI subsidiaries (MunnWorks, SteriLumen & LED), in talks [...]

Pages